Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Ryskalin L, Biagioni F, Busceti CL, Lazzeri G, Frati A, Fornai F
In brief, patients were adults who had been diagnosed with T2D 90 days before screening, had baseline HbA 1c above target (7.010.5% [5391 mmol/mol] in PIONEER 3 and 7.09.5% [5380 mmol/mol] in PIONEER 4, 5, 7 and 8) and were receiving stable doses of glucose-lowering background medication(s)
Since off-label use is not as extensively studied or approved by regulatory authorities, patients should be closely monitored for efficacy and safety
Ando Y, Shigiyama F, Hirose T, Kumashiro N
US$ 25.41
US$ 22.41
US$ 25.43
US$ 28.57
US$ 25.87
US$ 20.13
US$ 29.53
